Does Cigna Pay for GLP-1 Medications? (2026)
What Cigna pays for, what it asks of you first, what it costs when the answer is yes, and where to go when it is no.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Where Each Medication Stands[8]
| Medication | What Cigna does |
|---|---|
| Wegovy (semaglutide) | Cigna covers Wegovy on many commercial plans with prior authorization (IP0206 §III, effective 04/30/2026). Adult initial approval is 8 months if patient is >=18, has engaged in >=3 months of behavioral modification and dietary restriction, has BMI >=30 OR BMI >=27 with one of 11 weight-related comorbidities (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD/NAFLD, polycystic ovarian syndrome, or coronary artery disease), and uses Wegovy concomitantly with a reduced-calorie diet. Continuation/reauthorization is 1 year and requires documented >=5% baseline body-weight loss. Pediatric (>=12 to <18) initial 8-month approval requires BMI >=95th percentile + 3-month behavioral/diet trial; continuation requires >=1% BMI reduction. A separate MACE risk-reduction pathway (1-year approval) covers patients >=18 with BMI >=27 and established cardiovascular disease — no weight-loss requirement. |
| Ozempic (semaglutide) | Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate (verbatim): if criteria for previous use of an oral diabetes medication in the past 130 days are not met, OR patient is <18, coverage requires prior authorization. CRITICAL: single-entity metformin and Rybelsus do NOT satisfy the 130-day step. PA approval is 1 year if patient is >=18. |
| Zepbound (tirzepatide) | Covered per IP0206 §V (effective 04/30/2026) with the same 4-prong adult initial criteria as Wegovy: >=18, 3-month behavioral/diet trial, BMI >=30 OR BMI >=27 with one of the 11 comorbidities, concomitant lifestyle. Initial approval is 8 months; continuation is 1 year and requires >=5% baseline body-weight loss. Separate moderate-to-severe OSA-in-obesity pathway (1-year initial) requires AHI >=15 by sleep study, BMI >=30, and no central sleep apnea / Cheyne-Stokes; OSA continuation requires >=10% body-weight loss after >=1 year plus prescriber-attested OSA stability. Quantity limits per CNF 840 (current): 4 pens or vials per 28 days at retail; 12 per 84 days at home delivery — no overrides across all strengths. |
| Mounjaro (tirzepatide) | Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate (verbatim): if criteria for previous use of an oral diabetes medication in the past 130 days are not met, OR patient is <10 years of age, coverage requires prior authorization. CRITICAL: single-entity metformin and Rybelsus do NOT satisfy the step — a different oral antidiabetic must be in the lookback. PA approval is 1 year if patient is >=10 years of age. (Mounjaro minimum age was lowered from >=18 to >=10 effective 01/07/2026 per the policy History note.) |
| Foundayo (orforglipron) | Covered per IP0206 §II (effective 04/30/2026). Same 4-prong adult initial framework as Wegovy/Zepbound: >=18, 3-month behavioral/diet trial, BMI >=30 OR BMI >=27 with one of the 11 weight-related comorbidities, concomitant lifestyle. Initial approval is 8 months; continuation is 1 year and requires documented >=5% baseline body-weight loss. Foundayo is NOT yet listed in the standalone CNF 684 weight-loss PA policy as of 02/25/2026; IP0206 is the canonical source. |
| Copay when it is covered | $25-$75 / month |
After a Denial from Cigna
A refusal on Wegovy or Zepbound is not the end of the road. Licensed 503A pharmacies[7] dispense compounded semaglutide and tirzepatide at $149-$299 a month, well under what the brand costs. Two other things are worth knowing. With a prescription, a brand-name GLP-1 is generally an eligible HSA or FSA medical expense[5], and a good number of plan administrators will accept a compounded one on a Letter of Medical Necessity. The services listed below ship to all 50 states and usually write inside the week.
Large employers often self-fund, which puts the plan under ERISA rather than state insurance law and leaves the employer free to decide whether anti-obesity medication is covered at all[6]. If yours self-funds, the answer sits in the Summary Plan Description, in the GLP-1 language specifically.
Lodge the formal appeal with Cigna first. Ask your prescriber for a Letter of Medical Necessity that documents your BMI, any comorbidities, and the weight-loss attempts that did not work. Appeals carrying one overturn a real share of denials.
Every Cigna GLP-1 PA clause is reproduced word for word in our guide: the CNF 840 quantity limits, the Wegovy MACE pathway, the Zepbound OSA pathway, the change making Mounjaro available from ≥10 years old, how Foundayo (orforglipron) is handled, the comorbidity list of 11 conditions, and the step-therapy rule running 130 days that excludes single-entity metformin. Read it in the Cigna GLP-1 Prior Authorization Guide.
Cash-pay GLP-1 services if Cigna says no
Cash-pay compounded semaglutide and tirzepatide are not hard to find, and after a denial the monthly cost often lands under what a covered copay would have been. Our highest-ranked picks come first, then the longer list.
Our picks
Compare the top providers at a glance
Every row carries a logo, our editorial rating, price, the medications prescribed, and where the seller ships. Scan down a column and the list shortens fast.
- ★ Editor's Pick
semaglutide at $99/month, 48% under the register median
From /mo$99Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide - Best Budget
semaglutide at $99/month, 48% under the register median
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide - Nationwide Coverage
tirzepatide at $169/month, 37% under the register median
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide moving between compounded and brand without changing seller
From /mo$129Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatidesemaglutide at $99/month, 48% under the register median
From /mo$99Coverage49 statesMedicationsSemaglutideTirzepatide
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick semaglutide at $99/month, 48% under the register median | $99 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
Best Budget semaglutide at $99/month, 48% under the register median | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
Nationwide Coverage tirzepatide at $169/month, 37% under the register median | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
 moving between compounded and brand without changing seller | $129 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
 semaglutide at $99/month, 48% under the register median | $99 | SemaglutideTirzepatide | 49 states | Visit → |
The longer list of compounded options
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Kairos Aesthetic and Longevity Medicine
Best for: a published state list — 1 of 50 — when most of the register publishes none
Editorial score · methodology
Get StartedRead full Kairos Aesthetic and Longevity Medicine review →Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Trimrose
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- Off-label use · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Cigna coverage changes
We will email you if Cigna changes its GLP-1 rules.
Sources & methodology — as of August 2026
- 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 2.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 3.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 4.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
- 6.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 7.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 8.GLP Watchdog insurer coverage index (manually curated formulary data)— GLP Watchdog.